Pharma Neutral 5

ResMed’s $270.64 Consensus Hides a 30% Spread in Analyst Targets

· 3 min read · Verified by 2 sources · By Biotech Intelligence Brief Editorial
Share

Key Takeaways

  • Biotech and life sciences investors face a paradox: ResMed’s stalwart medical device business is underpinned by low debt and high margins, yet analyst targets range from $225 to $321 as GLP-1 therapies threaten its patient base.

Mentioned

ResMed company RMD Wells Fargo & Company company WFC Morgan Stanley company MS Citigroup company C Royal Bank of Canada company JPMorgan Chase & Co. company JPM Robert W. Baird company Weiss Ratings company The Goldman Sachs Group company GS MarketBeat technology

Key Intelligence

Key Facts

  1. 1Wells Fargo reduced ResMed price target from $227 to $225, keeping an Equal Weight rating, implying 2.45% upside from prior close.
  2. 2Consensus analyst rating stands at Moderate Buy with an average price target of $270.64, based on 1 Strong Buy, 9 Buys, and 6 Holds.
  3. 3Morgan Stanley cut its target to $230 (from $286) and Citigroup to $270 (from $340) in June, reflecting significant downward revisions.
  4. 4ResMed shares opened at $219.62 on July 8, 2026, with a 50-day moving average of $201.12 and 200-day moving average of $228.95.
  5. 5The company has a market cap of $31.86B, P/E of 21.18, PEG of 1.28, debt-to-equity of 0.06, and a beta of 0.78.
  6. 6Royal Bank of Canada raised its target to $321 in May, maintaining an Outperform rating, highlighting the wide dispersion in analyst outlooks.
Firm
Wells Fargo Equal Weight $227 $225 Jul 8
Morgan Stanley Equal Weight $286 $230 Jun 17
Citigroup Buy $340 $270 Jun 15
RBC Capital Outperform $314 $321 May 1
Robert W. Baird N/A N/A $225 May 1
Analyst Consensus Sentiment

Analysis

For biotech investors accustomed to binary clinical events, ResMed presents a different kind of risk: a slow-moving competitive threat from obesity drugs. The wide dispersion in analyst targets—from Wells Fargo’s $225 to RBC’s $321—mirrors the uncertainty typical of a pivotal drug trial, but applied to a medtech giant with a $31.86B market cap.

Wells Fargo & Company lowered its price target on ResMed (NYSE:RMD) to $225.00 from $227.00 while maintaining an 'equal weight' rating, signaling a cautious stance on the medical device leader that sits at the heart of the sleep apnea and respiratory care market. The modest $2 cut, reported July 8, 2026, comes amid a broader recalibration of analyst expectations for ResMed, with multiple Wall Street firms slashing targets over the past two months—Morgan Stanley to $230 from $286, Citigroup to $270 from $340—while others like Royal Bank of Canada raised theirs to $321. The result is a highly divided analyst community: 10 Buy or Strong Buy ratings against 6 Holds, producing an average consensus target of $270.64, which implies a 23% upside from the $219.62 opening price on Wednesday.

The wide dispersion in analyst targets—from Wells Fargo’s $225 to RBC’s $321—mirrors the uncertainty typical of a pivotal drug trial, but applied to a medtech giant with a $31.86B market cap.

This polarization reflects uncertainty about ResMed’s growth trajectory. Historically, the company benefited enormously from a competitor’s massive CPAP recall (Philips) that drove market share gains and boosted revenues. However, that tailwind is maturing. A new threat looms in the form of GLP-1 weight loss drugs such as semaglutide, which could meaningfully shrink the addressable pool of sleep apnea patients if obesity—a major risk factor—is treated pharmacologically. Studies on tirzepatide’s efficacy in obstructive sleep apnea have already stirred debate, and while ResMed management points to low therapy penetration rates globally as a cushion, the market is pricing in a potential demand slowdown. The stock’s 50-day moving average of $201.12 has trended upward recently, hinting at short-term recovery, but it remains well below the 200-day average of $228.95 and far from its 12-month high of $293.81.

What to Watch

ResMed’s financials remain robust: a market cap of $31.86 billion, P/E ratio of 21.18, negligible debt-to-equity of 0.06, and solid liquidity metrics (current ratio 3.01, quick ratio 2.33). The company last reported earnings on April 30, 2026, and while details from that report are not contained in these analyst notes, the subsequent wave of target cuts suggests that forward guidance or secular headwinds disappointed. The 1.28 PEG ratio indicates expectations of moderate growth, but the beta of 0.78 implies the stock is less volatile than the broader market, making it an interesting defensive play within healthcare if the device cycle proves resilient.

For investors, the divergent views underscore the importance of monitoring upcoming clinical data on GLP-1s in sleep apnea and any ResMed-specific catalysts—new product launches, market expansion in emerging economies, or digital health integrations—that could re-rate the stock. The Wells Fargo target, while low, still offers a slim 2.45% upside, reflecting an expectation that the stock already prices in many risks. The deeper question is whether the consensus $270.64 target is too optimistic or the pessimistic targets are overly conservative. The answer will hinge on how quickly the obesity-drug narrative materializes into actual CPAP prescription declines.

Sources

Sources

Based on 2 source articles

Cite This Page

"ResMed’s $270.64 Consensus Hides a 30% Spread in Analyst Targets." Biotech Intelligence Brief, July 10, 2026. https://getbiobrief.com/story/resmed-analyst-divide-biotech-investment

Related Stories

Pharma

49-Year Species Rule Ends: Biotech’s Natural Drug Library Faces Extinction Risk

The U.S. Interior Department’s cancellation of automatic ESA protections for threatened species could accelerate biodiversity loss, directly threatening the natural sources of many pharmaceuticals. Bioprospecting and natural product R&D face heightened uncertainty as habitat destruction outpaces species discovery. The rule change adds regulatory complexity for biotech companies seeking access to rare organisms.

Pharma

Only 92 Deals: Big Pharma's TrumpRx Offering Covers Under 12% of Its 800+ Drug Stable

TrumpRx, the Trump administration's drug discount website, has secured voluntary pricing deals on only 92 brand-name drugs—less than 12% of the 800-plus products from 17 major pharmaceutical companies. High-cost therapies for inflammatory diseases, HIV, and cancer are largely excluded, raising doubts about industry's willingness to compromise on pricing without legislation.

Pharma

5,100 Suspected Cyclospora Cases Drive Demand for Rapid Diagnostics and New Therapies

The CDC's health alert on a cyclosporiasis outbreak with 5,100 suspected cases presents urgent needs in the biotech sector for rapid diagnostics, antiparasitic drug development, and food safety technologies. The parasite Cyclospora cayetanensis, with its long incubation period, challenges traditional detection methods, while treatment relies on a decades-old antibiotic. Innovators could capitalize on multiplex PCR panels and next-generation sequencing for outbreak tracking.

Pharma

Novartis, Roche Face 50% PBS Price Cut on MS Drugs as Briumvi Triggers Review

A July 2026 Australian PBS review for Roche's Ocrevus and Novartis’s Kesimpta could reduce government reimbursement by up to 50%, triggered by reference pricing with new low-cost entrant Briumvi. Manufacturers risk margin erosion or market withdrawal.

How we covered this story

Every story in our biotech coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.

Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the biotech space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.

Signal on this pageWhat it tells you
Verified by N sourcesIndependent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly.
Impact score (1-10)Regulatory + financial + operational weight. 8+ signals an experienced-operator action item.
SentimentFive-tier classification trained on labeled biotech-specific corpora.
TimelineWhere applicable, the related-events sequence that contextualizes today's development.